Morgan Stanley releases report on Giant Biotech（ http://2367.HK ）The tactical view is bullish, believing that the probability of its stock price rising in the next 30 days is as high as 70% -80%. The key factor is that the current stock price has not responded positively to strong sales in the second quarter and the listing of the first recombinant collagen injection, and the valuation is undervalued. Sales in the first half of the year are expected to increase by approximately 20% month on month. The target price is set at HKD 43, and the current stock price is only HKD 27.04, corresponding to a 12 times future 12-month P/E ratio and a dividend yield of 4-5%. The market's concerns about the overall tightening of regulation and intensified competition in the medical beauty industry may have led it to overlook the strong product cycle and upcoming heavyweight catalyst of Juzi Biotechnology.